Pulmonary arterial hypertension: The mandatory role of the cardiologist

Hellenic Journal of Cardiology

Volumn 48, Issue 3, 2007, Pages 123-126

  Adamopoulos, Stamatis ^a   Georgiadou, Panagiota ^a   Theodorakis, George ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Clinical cardiology; Pulmonary arterial hypertension; Right heart failure

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; SILDENAFIL; SITAXSENTAN;

ARTERIAL PRESSURE; CARDIOLOGIST; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; EDITORIAL; ELECTROCARDIOGRAM; EXERCISE; HEART CATHETERIZATION; HEART OUTPUT; HEMODYNAMICS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; X RAY; CARDIOLOGY; PATHOPHYSIOLOGY; PHYSICIAN ATTITUDE; TREATMENT OUTCOME;

CARDIOLOGY; HUMANS; HYPERTENSION, PULMONARY; PHYSICIAN'S ROLE; TREATMENT OUTCOME;

EID: 34548022863     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Rich S: Primary pulmonary hypertension. Prog Cardiovasc Dis 1988; 31: 205-238.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension - results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
3. Recommendations on the management of pulmonary hypertension in clinical practice: Heart 2001; 86 (Suppl 1): i1-i13.
4. Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
5. Rich S, Dantzker DR, Ayres SM, et al: Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
6. Humbert M, Nunes H, Sitbon O, Parent F, Herve P, Simon-neau G: Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-475.
7. Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC: Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002; 122: 524-527.
8. Raymond RJ, Hinderliter AL, Willis PW, et al: Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-1219.
9. Rajdev S, Nanda NC, Patel V, et al: Tissue Doppler assessment of longitudinal right and left ventricular strain and strain rate in pulmonary artery hypertension. Echocardiography 2006; 23: 872-879.
10. Ley S, Kreitner KF, Fink C, Heussel CP, Borst MM, Kauczor HU: Assessment of pulmonary hypertension by CT and MR imaging. Eur Radiol 2004; 14: 359-368.
11. Weir EK, Rubin LJ, Ayres SM, et al: The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.
12. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
13. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M: The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112: 714-721.
14. Rich S, Seidlitz M, Dodin E, et al: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792.
15. McLaughlin VV, Genthner DE, Panella MM, Rich S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
16. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
17. Channick R, Badesch DB, Tapson VF, et al: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001; 20: 262-263.
18. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860-1868.
19. Galie N, Badesch D, Oudiz R, et al: Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.
20. Galie N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
21. de Carvalho AC, Hovnanian AL, Fernandes CJ, Lapa M, Jardim C, Souza R: Tadalafil as treatment for idiopathic pulmonary arterial hypertension. Arq Bras Cardiol 2006; 87: e195-197.
22. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E: Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-334.
23. Galie N, Torbicki A, Barst R, et al: Task Force: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
24. Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
25. Torbicki A, Kurzyna M, Kuca P, et al: Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.
26. Wensel R, Opitz CF, Anker SD, et al: Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319-324.